Dimapur district continues to top the list of TB cases in the state with an estimated 1,963 patients in 2024 where a total of 45 were registered as death cases and 104 as Lost to Follow-Up ...

In today's Morning Rounds newsletter, a frontrunner to lead NIH’s largest institute, the many lives of acetaminophen, and more.

It's a challenging environment for job seekers, with many professionals wondering if they should press forward with their careers or pivot to something entirely different. On this week's episode of ...

A public consultation is set to gather views on opening a drug consumption room in Edinburgh, similar to Glasgow's Thistle centre.

Princess Margaret was something of a cultural icon in her day. She was applauded for her unusual fashion choices, critiqued for her love of parties, and beloved for her exuberant personality. If Queen ...

Hit the right sale day and you’ll walk out with bags full of treasures for pocket change! Where: 410 El Camino Ave, Sacramento, CA 95815 Crossroads Trading in San Francisco breaks every thrift store ...

Texas Thrift in Arlington is a treasure hunter’s paradise. Walking in, you’re greeted by a store so big you might need a map. The aisles seem to go on forever, each one filled with potential finds.

Being out of care doesn’t have to be permanent, and many people can restart HIV treatment. The sooner PWH restart treatment, the better, as restarting and staying on HIV treatment can help them reach ...

Lots of scholarship assumes that partners in higher-quality relationships work together to reduce health-related risks. A new study tested this assumption.

Crypto is no longer a niche topic. It's gone from online forums to the dinner table. But the data shows a serious disconnect. While institutional money floods the market, a staggering 60% of US crypto ...

“I want what I want when I want it.” This tune, from a popular song more than a century ago, captures something timeless about human desire. Cravings feel immediate, even irresistible: the feeling ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...